Clinical trials · Maryland
Allergy clinical trials in Maryland
We’re tracking 134 recruiting allergy studies with a site in Maryland — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies in Maryland
- NCT07271381Recruiting
Testing how allergens and everyday toxins affect your body
This study looks at how common allergens and everyday toxins from things like cleaning products affect your skin, gut, and airways. It may help find ways to prevent or manage allergies and related health issues.
Bethesda, MarylandAges 18–80 - NCT07202598RecruitingPhase 2
Testing emapalumab for gut inflammation in APECED
This trial tests a drug called emapalumab to treat chronic gut inflammation (enteritis) in people with APECED, a rare immune disorder. It aims to see if the drug can help when other treatments haven't worked.
Bethesda, MarylandAges 2–75 - NCT07113743Enrolling by invitationPhase 1/Phase 2
Gene therapy for x-linked chronic granulomatous disease
This trial tests a new gene therapy for X-linked chronic granulomatous disease (CGD), a condition where the immune system cannot fight certain infections. The treatment uses your own blood stem cells, which are modified in the lab to help your body produce working immune cells.
Bethesda, MarylandAges 3–60 - NCT07110532RecruitingPhase 1
A study of flu virus exposure in healthy adults
This trial tests how the body reacts to a specific flu virus (pH1N1) in a controlled setting. Healthy volunteers are exposed to the virus to help researchers understand the infection and test treatments. You will be monitored closely and given antiviral medication if needed.
Baltimore, MarylandAges 18–55 - NCT07108387RecruitingPhase 2
Stopping or reducing tocilizumab for well-controlled giant cell arteritis
This study compares stopping tocilizumab (Actemra) completely versus reducing the dose in people whose giant cell arteritis has been well controlled for at least a year. The goal is to find out which approach keeps the disease in remission while reducing medication side effects.
Baltimore, MarylandAges 50 years+ - NCT07111078RecruitingPhase 1
New Flu Vaccine (Stem) with or without Booster
This trial tests a new type of flu vaccine that targets a part of the virus that doesn't change much (the stem). It is given with or without a special booster, and researchers want to see if it provides broader protection against different flu strains.
Bethesda, MarylandAges 18–50 - NCT07103746RecruitingPhase 2
Ublituximab for antibody-positive IMNM
This study tests an investigational medication called ublituximab (an infusion) for people with a rare autoimmune muscle disease called IMNM. It aims to reduce muscle weakness and damage by targeting specific immune cells (B cells). To join, you need a recent diagnosis (within 1 year), specific antibodies, and be on limited other medications.
Baltimore, MarylandAges 18 years+ - NCT07059091RecruitingPhase 2
Allergy medicine for COPD with indoor allergies
This study tests if omalizumab, an allergy medicine, can help people with COPD who are allergic to common indoor allergens and have had recent flare-ups. It aims to see if reducing allergic reactions can improve COPD control.
Baltimore, MarylandAges 40 years+ - NCT07046806RecruitingPhase 1/Phase 2
Oral deucrictibant for hereditary angioedema attacks
This trial tests an oral medication called deucrictibant to prevent and treat swelling attacks in people with hereditary angioedema. It may help reduce the number and severity of attacks.
Wheaton, MarylandAges 18–75 - NCT07040319RecruitingPhase 1/Phase 2
Hepatitis C treatment study for pregnant women
This study tests a medicine called glecaprevir/pibrentasvir for pregnant women with hepatitis C, with or without HIV. It aims to see how the medicine works in the body and if it is safe during pregnancy.
Baltimore, MarylandAges 16–45 - NCT06974877RecruitingPhase 1
PET/CT Imaging for Amyloid in CAPS on Anakinra
This trial uses a special PET/CT scan to see if a radioactive tracer can measure changes in amyloid buildup in people with CAPS who have developed a skin reaction to anakinra. It may help doctors understand how the disease is affecting your organs.
Bethesda, MarylandAges 18–120 - NCT06959771RecruitingPhase 1/Phase 2
Gene therapy for CD40L deficiency (Hyper-IgM syndrome) - single patient study
This trial tests a new gene therapy that uses a person's own blood stem cells and T cells, which are corrected with a gene-editing tool called base editing. It is designed for people with a specific CD40L gene mutation who also have liver problems and portal hypertension. The goal is to see if this treatment can improve their immune system and liver health.
Bethesda, MarylandAges 37–120 - NCT06934200RecruitingPhase 2
Xolair for food allergy in people with high IgE
This study tests if omalizumab (Xolair), an injectable medicine that blocks allergy antibodies, can help people with food allergies tolerate small amounts of their trigger foods. It's for people with high total IgE levels who were not eligible for a related study.
Baltimore, MarylandAges 1–55 - NCT06908096RecruitingPhase 1
EBV nanoparticle vaccine study for healthy adults
This study tests two experimental vaccines against Epstein-Barr virus (EBV), the germ that causes mono. You may be able to join if you are a healthy adult aged 18–29 and haven't had an EBV vaccine before. The trial will check if the vaccines are safe and trigger an immune response.
Bethesda, MarylandAges 18–29 - NCT06908083Enrolling by invitationPhase 1
Stopping HIV treatment with antibody therapy
This trial tests whether a combination of powerful antibodies (bNAbs) can help control HIV after stopping standard HIV treatment. Participants will pause their daily HIV medications while receiving these antibodies, and doctors will closely monitor their immune system and virus levels. It's for people who are already well-controlled on HIV treatment and have participated in a specific earlier study.
Bethesda, MarylandAges 18–70 - NCT06863142RecruitingPhase 1
Testing a new flu vaccine with or without adjuvant
This study tests a new investigational flu vaccine (FluMos-v2) with or without an adjuvant (ALFQ) to see how safe, tolerable, and effective it is. It may help protect against multiple flu strains.
Bethesda, MarylandAges 18–50 - NCT06851767Enrolling by invitationPhase 1/Phase 2
Gene therapy for X-linked severe combined immunodeficiency
This study tests a gene therapy to treat X-linked severe combined immunodeficiency (X-SCID) without a stem cell transplant from a matched sibling. It aims to improve immune function and reduce infections using your own stem cells modified to carry the correct gene.
Bethesda, MarylandAges 3–99 - NCT06819176RecruitingPhase 1
Testing a new drug to shrink hidden HIV in people with suppressed virus
This study tests whether adding a new anti-HIV drug called lenacapavir to your regular HIV treatment can shrink the hidden reservoir of virus in your body. This could be a step toward a cure.
Bethesda, MarylandAges 18–75 - NCT06730126RecruitingPhase 2
Soquelitinib for ALPS-FAS-related swelling and low blood counts
This trial tests an investigational drug called soquelitinib to see if it can shrink enlarged lymph nodes and improve low blood cell counts in people with ALPS-FAS. It may offer a new treatment option for those who have active symptoms.
Bethesda, MarylandAges 16–120 - NCT06607003RecruitingPhase 1
Testing a malaria infection in healthy adults
This study gives healthy adults who have never had malaria a controlled infection with the parasite that causes malaria, to see if it is safe and if mosquitoes can pick up the parasite from them. It may help develop new ways to prevent malaria.
Bethesda, MarylandAges 18–54 - NCT06517693RecruitingPhase 1
HIV antibody safety study for newborns at risk
This study tests whether giving a combination of two lab-made antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV during pregnancy is safe and how the body processes them. It may help protect infants from getting HIV after birth.
Baltimore, MarylandAges Up to 3 days - NCT06477653RecruitingPhase 2
Dupilumab for hypereosinophilic syndrome with ongoing symptoms
This trial tests if dupilumab, added to your current treatment, can help with remaining symptoms of hypereosinophilic syndrome (HES) like asthma, eczema, nasal polyps, or eosinophilic esophagitis. You may qualify if you're already on a biologic therapy that lowers eosinophils but still have bothersome symptoms.
Bethesda, MarylandAges 18–99 - NCT06476132RecruitingPhase 2
Belumosudil for lung transplant patients at risk of chronic rejection
This trial tests whether the drug Belumosudil can help prevent chronic lung rejection in people who recently had a lung transplant and showed signs of early rejection. It may improve long-term lung health.
Baltimore, MarylandAges 12 years+ - NCT06339177Recruiting
HLH study looking at immune system and genes
This study is for people with hemophagocytic lymphohistiocytosis (HLH), a condition where the immune system becomes overactive. Researchers want to collect medical data and blood samples to better understand HLH and find better ways to diagnose and treat it.
Bethesda, MarylandAges 18–120
Allergy trials by city in Maryland
Where these studies are running in Maryland
Institutions with a site for the recruiting allergy studies listed above.
- National Institutes of Health Clinical Center · 15 studies
- Johns Hopkins University · 2 studies
- Institute For Asthma & Allergy
- Johns Hopkins (Site #: 71119)
- Johns Hopkins Hospital: Division of Rheumatology
- Johns Hopkins Hospital: Division of Rheumatology Vasculitis Center
- Johns Hopkins University Baltimore
- Site 5092, Johns Hopkins University Baltimore
What taking part in a allergy study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Allergy trials in other states
Common questions
- Are there allergy clinical trials in Maryland?
- Yes. We're currently tracking 134 recruiting allergy studies with a site in Maryland, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a allergy study in Maryland?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Maryland to take part?
- Not necessarily. These studies have a site in Maryland, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a allergy trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New allergy studies open in Maryland regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.